Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 42

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 42
---
”) with MSD. Under the CTCSA, we are collaborating with MSD regarding the conduct of our international Phase 2 trial for our compounds, IO102 and IO103, in combination with MSD’s pembrolizumab, a humanized anti-human PD-1 monoclonal antibody, for the treatment of metastatic NSCLC, SCCHN or UBC (the “Trial”). Under the CTCSA, we are acting as the sponsor of the Trial at our cost, and MSD is supplying pembrolizumab for use in the Trial. Neither party has any obligation to reimburse costs incurred by the other party in connection with the Trial or the supply of pembrolizumab, except upon certain breach or early termination events.

The CTCSA remains in effect until we provide MSD with top-line results and a final report of the results, promptly after the Trial is completed, unless terminated earlier by either party for the other party’s material breach if such party fails to cure such breach within the specified cure period, or upon certain other occurrences specified in the CTCSA.

September 2021 Agreement for the Phase 3 IOB-013/KN-D18 Trial

In September 2021, we entered into an additional Clinical Trial Collaboration and Supply Agreement (the “MSD Agreement”) with MSDIG, and MSDIB to collaborate regarding the conduct of our international Phase 3 trial for the Company’s compounds, IO102-IO103, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, for the treatment of advanced melanoma (the “MSD Study”). Each party is required to use commercially reasonable efforts to supply its compound, at its own cost, for use in the MSD Study. Under the MSD Agreement, we are acting as the sponsor of the MSD Study at our cost (except for the cost of the supply of KEYTRUDA® from MSD and certain other internal costs incurred by MSD in conducting the MSD Study). 

Under the MSD Agreement, all clinical data besides the data arising from the arm of the MSD Study involving only KEYTRUDA® are jointly owned by us and MSD. All inventions relating to the combined use of IO102-IO103 and KEYTRUDA® arising from the MSD Study are also jointly owned by us and MSD. We do not have the right under these jointly owned inventions to research, develop or commercialize any PD-1 antagonist and MSD does not have the right under the jointly owned inventions to research, develop or commercialize any peptide vaccine, such as